Literature DB >> 10103035

Nucleoside diphosphate kinase activity in soluble transducin preparations biochemical properties and possible role of transducin-beta as phosphorylated enzyme intermediate.

J F Klinker1, R Seifert.   

Abstract

Known nucleoside diphosphate kinases (NDPKs) are oligomers of 17-23-kDa subunits and catalyze the reaction N1TP + N2DP --> N1DP + N2TP via formation of a histidine-phosphorylated enzyme intermediate. NDPKs are involved in the activation of heterotrimeric GTP-binding proteins (G-proteins) by catalyzing the formation of GTP from GDP, but the properties of G-protein-associated NDPKs are still incompletely known. The aim of our present study was to characterize NDPK in soluble preparations of the retinal G-protein transducin. The NDPK is operationally referred to as transducin-NDPK. Like known NDPKs, transducin-NDPK utilizes NTPs and phosphorothioate analogs of NTPs as substrates. GDP was a more effective phosphoryl group acceptor at transducin-NDPK than ADP and CDP, and guanosine 5'-[gamma-thio]triphosphate (GTP[S]) was a more effective thiophosphoryl group donor than adenosine 5'-[gamma-thio]triphosphate (ATP[S]). In contrast with their action on known NDPKs, mastoparan and mastoparan 7 had no stimulatory effect on transducin-NDPK. Guanosine 5'-[beta, gamma-imido]triphosphate (p[NH]ppG) potentiated [3H]GTP[S] formation from [3H]GDP and ATP[S] but not [3H]GTP[S] formation from [3H]GDP and GTP[S]. Depending on the thiophosphoryl group acceptor and donor, [3H]NTP[S] formation was differentially regulated by Mg2+, Mn2+, Co2+, Ca2+ and Zn2+. [gamma-32P]ATP and [gamma-32P]GTP [32P]phosphorylated, and [35S]ATP[S] [35S]thiophosphorylated, a 36-kDa protein comigrating with transducin-beta. p[NH]ppG potentiated [35S]thiophosphorylation of the 36-kDa protein. 32P-labeling of the 36-kDa protein showed characteristics of histidine phosphorylation. There was no evidence for (thio)phosphorylation of 17-23-kDa proteins. Our data show the following: (a) soluble transducin preparations contain a GDP-prefering and guanine nucleotide-regulated NDPK; (b) transducin-beta may serve as a (thio)phosphorylated NDPK intermediate; (c) transducin-NDPK is distinct from known NDPKs and may consist of multiple kinases or a single kinase with multiple regulatory domains.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10103035     DOI: 10.1046/j.1432-1327.1999.00209.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  6 in total

Review 1.  Interaction of nucleoside diphosphate kinase B with heterotrimeric G protein betagamma dimers: consequences on G protein activation and stability.

Authors:  Thomas Wieland
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-01-03       Impact factor: 3.000

Review 2.  Advances in development of new tools for the study of phosphohistidine.

Authors:  Mehul V Makwana; Richmond Muimo; Richard Fw Jackson
Journal:  Lab Invest       Date:  2017-12-04       Impact factor: 5.662

3.  Down-regulation of expression and function of nucleoside diphosphate kinase in insulin-secreting beta-cells under in vitro conditions of glucolipotoxicity.

Authors:  Rajakrishnan Veluthakal; Madathilparambil V Suresh; Anjaneyulu Kowluru
Journal:  Mol Cell Biochem       Date:  2009-04-15       Impact factor: 3.396

Review 4.  High energy phosphate transfer by NDPK B/Gbetagammacomplexes--an alternative signaling pathway involved in the regulation of basal cAMP production.

Authors:  Hans-Joerg Hippe; Thomas Wieland
Journal:  J Bioenerg Biomembr       Date:  2006-08       Impact factor: 3.853

Review 5.  Emerging roles for protein histidine phosphorylation in cellular signal transduction: lessons from the islet beta-cell.

Authors:  Anjaneyulu Kowluru
Journal:  J Cell Mol Med       Date:  2008-04-08       Impact factor: 5.310

6.  Alterations in energy metabolism, neuroprotection and visual signal transduction in the retina of Parkinsonian, MPTP-treated monkeys.

Authors:  Laura Campello; Julián Esteve-Rudd; Roque Bru-Martínez; María Trinidad Herrero; Emiliano Fernández-Villalba; Nicolás Cuenca; José Martín-Nieto
Journal:  PLoS One       Date:  2013-09-05       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.